BRPI0718850A2 - METHODS OF TREATING, DIAGNOSING OR DETECTION CANCER - Google Patents
METHODS OF TREATING, DIAGNOSING OR DETECTION CANCERInfo
- Publication number
- BRPI0718850A2 BRPI0718850A2 BRPI0718850-1A2A BRPI0718850A BRPI0718850A2 BR PI0718850 A2 BRPI0718850 A2 BR PI0718850A2 BR PI0718850 A BRPI0718850 A BR PI0718850A BR PI0718850 A2 BRPI0718850 A2 BR PI0718850A2
- Authority
- BR
- Brazil
- Prior art keywords
- diagnosing
- treating
- methods
- detection cancer
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85888206P | 2006-11-14 | 2006-11-14 | |
PCT/US2007/084293 WO2008061020A2 (en) | 2006-11-14 | 2007-11-09 | Methods of treating, diagnosing or detecting cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0718850A2 true BRPI0718850A2 (en) | 2014-02-25 |
Family
ID=39402414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0718850-1A2A BRPI0718850A2 (en) | 2006-11-14 | 2007-11-09 | METHODS OF TREATING, DIAGNOSING OR DETECTION CANCER |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2084540A2 (en) |
JP (1) | JP2010509368A (en) |
KR (1) | KR20090080082A (en) |
CN (1) | CN101558308A (en) |
AU (1) | AU2007319360A1 (en) |
BR (1) | BRPI0718850A2 (en) |
CA (1) | CA2668714A1 (en) |
MX (1) | MX2009005058A (en) |
WO (1) | WO2008061020A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
RS54215B1 (en) | 2005-10-31 | 2015-12-31 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
SG190568A1 (en) | 2008-09-26 | 2013-06-28 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
JP2013530929A (en) | 2010-04-01 | 2013-08-01 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Frizzled binders and uses thereof |
EP2694963B1 (en) | 2011-04-01 | 2017-08-02 | Qiagen | Gene expression signature for wnt/b-catenin signaling pathway and use thereof |
JP5944994B2 (en) * | 2011-08-12 | 2016-07-05 | オメロス コーポレーション | Anti-FZD10 monoclonal antibodies and methods for their use |
JP6155255B2 (en) * | 2012-04-17 | 2017-06-28 | Hoya株式会社 | FZD10 binding peptide |
EP2911691B1 (en) | 2012-10-23 | 2018-10-10 | OncoMed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
CN103048446B (en) * | 2012-12-25 | 2015-02-04 | 苏州浩欧博生物医药有限公司 | Luteinizing hormone nano-magnetic particle chemiluminescence assay kit and preparation method thereof and assay method thereof |
EP2950885B1 (en) | 2013-02-04 | 2018-11-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
EP2997378B1 (en) * | 2013-05-16 | 2018-08-08 | Kyoto University | Method for determining prognosis of cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004020668A2 (en) * | 2002-08-30 | 2004-03-11 | Oncotherapy Science, Inc. | Method for treating synovial sarcoma |
ES2381841T3 (en) * | 2003-07-11 | 2012-06-01 | Oncotherapy Science, Inc. | Method to treat synovial sarcoma |
EP2044123B1 (en) * | 2006-06-21 | 2013-03-13 | Oncotherapy Science, Inc. | Tumor-targeting monoclonal antibodies to fzd10 and uses thereof |
-
2007
- 2007-11-09 CN CNA2007800421795A patent/CN101558308A/en active Pending
- 2007-11-09 BR BRPI0718850-1A2A patent/BRPI0718850A2/en not_active Application Discontinuation
- 2007-11-09 MX MX2009005058A patent/MX2009005058A/en not_active Application Discontinuation
- 2007-11-09 AU AU2007319360A patent/AU2007319360A1/en not_active Abandoned
- 2007-11-09 CA CA002668714A patent/CA2668714A1/en not_active Abandoned
- 2007-11-09 WO PCT/US2007/084293 patent/WO2008061020A2/en active Application Filing
- 2007-11-09 KR KR1020097009781A patent/KR20090080082A/en not_active Application Discontinuation
- 2007-11-09 JP JP2009536514A patent/JP2010509368A/en active Pending
- 2007-11-09 EP EP07871425A patent/EP2084540A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
MX2009005058A (en) | 2009-05-25 |
EP2084540A2 (en) | 2009-08-05 |
AU2007319360A1 (en) | 2008-05-22 |
KR20090080082A (en) | 2009-07-23 |
WO2008061020A3 (en) | 2008-08-07 |
CA2668714A1 (en) | 2008-05-22 |
WO2008061020A9 (en) | 2008-11-13 |
WO2008061020A2 (en) | 2008-05-22 |
CN101558308A (en) | 2009-10-14 |
JP2010509368A (en) | 2010-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0718850A2 (en) | METHODS OF TREATING, DIAGNOSING OR DETECTION CANCER | |
BRPI0809137A2 (en) | methods of diagnosing, endometrial cancer and precancer classify and treat | |
ZA200808669B (en) | Methods of treating, diagnosing or detecting cancer | |
CR10667A (en) | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER | |
WO2010017515A3 (en) | Breast cancer specific markers and methods of use | |
BRPI0815588A2 (en) | POLYORGANOSYLOXAN-POLYURERIA AND / OR POLYORGANOSYL-XANO-POLYURETHANE COMPOUNDS | |
BRPI0920104A2 (en) | solution or wastewater treatment | |
BRPI0719202A2 (en) | Diagnosis and treatment of cancer using antiereg antibody | |
BRPI0715763A2 (en) | treating or preventing cancers by overexpressing reg4 or kiaa0101 | |
BRPI0717082A2 (en) | HYDROCARBON GAS PROCESSING | |
BRPI0814307A2 (en) | PRESBIOPIC TREATMENT SYSTEM | |
BRPI0813364A2 (en) | DIAGNOSTIC METHODS AND CANCER TREATMENT. | |
ES2322882B1 (en) | INHIBITING PEPTIDES OF NEURONAL EXOCITOSIS. | |
BRPI0811775A2 (en) | POLYCARBONATE COMPOUNDS-AND / OR POLYURETHANE-POLYORGANOSILOXANE | |
BRPI0817779A2 (en) | Hydrocarbon Gas Processing | |
BRPI0921122A2 (en) | prostate therapy system. | |
BRPI0921422A2 (en) | prostate therapy system. | |
BRPI0906975A2 (en) | Toothbrush for the treatment and / or detection of microbes. | |
EP2147124A4 (en) | Epigenetic biomarkers for early detection, therapeutic effectiveness, and relapse monitoring of cancer | |
WO2008073899A3 (en) | Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis | |
BRPI0814849A2 (en) | COMPACT WASH GUT SYSTEM | |
BRPI0917321A2 (en) | prevention, treatment and diagnosis of p. gingivalis | |
BRPI0813681A2 (en) | DETECTION OF NEMATELMINTH COPROANTIGEN | |
EP2016172A4 (en) | Diagnostic methods for determining treatment | |
BRPI0822002A2 (en) | treatment of colon disease or prevention of colorectal carcinoma with imidazoquinoline derivatives. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |